Vannair Dosage/Direction for Use

Asthma: Vannair pMDI taken as regular maintenance treatment, with a separate rapid-acting bronchodilator as rescue. Patients should be advised to have their separate rapid-acting bronchodilator available for rescue use at all times.
Increasing use of rescue bronchodilators indicates a worsening of the underlying condition and warrants reassessment of the asthma therapy. The dosage of Vannair pMDI should be individualised according to disease severity. When control of asthma has been achieved, the dose should be titrated to the lowest dose at which effective asthma control is maintained.
Adults and adolescents (12 years and older): Vannair pMDI 80/4.5: 2 inhalations of Vannair pMDI 80/4.5 twice daily. The maximum recommended daily maintenance dose is 4 inhalations (2 inhalations twice daily corresponding to 320 μg budesonide / 18 μg formoterol).
Vannair pMDI 160/4.5: 2 inhalations of Vannair pMDI 160/4.5 twice daily. The maximum recommended daily maintenance dose is 4 inhalations (2 inhalations twice daily corresponding to 640 μg budesonide / 18 μg formoterol).
COPD - Adults: 2 inhalations of Vannair pMDI 160/4.5 twice daily. The maximum recommended daily dose is 4 inhalations (corresponding to 640 μg budesonide / 18 μg formoterol).
Special patient populations: Renal Impairment: There are no data available for use of Vannair pMDI in patients with renal impairment.
Hepatic Impairment: There are no data available for use of Vannair pMDI in patients with hepatic impairment. As budesonide and formoterol are primarily eliminated via hepatic metabolism, an increased systemic availability can be expected in patients with severe liver disease.
Elderly: There is no need to adjust the dose in elderly patients.
Use in paediatric patients: Vannair pMDI is not recommended for children below 12 years of age.
General information: For optimal benefit the patient should be instructed to take Vannair pMDI even when asymptomatic.